

Impact of COVID-19 on cellular therapies in Germany: a DAG-HSZT survey

(Feb 2021)




Participation



participating centers


Did the corona pandemic have any impact on your work within the past 12 months?




February – May 2020: **74%**
June – October 2020: **61%**
since November 2020: **70%**

SCT scheduling


Autologous SCTs for multiple myeloma were...



Allogeneic SCTs were...




The main reason for a postponement of allogeneic SCT was:




Cryopreservation I


We are currently cryopreserving allogeneic stem cell products...



Were there any complications due to cryopreservation?




If yes, which?




Cryopreservation II

Did you have logistical difficulties with fresh allogeneic stem cell products?




Did you have to cancel or postpone allogeneic SCTs due to a SARS-CoV-2 infection / contact / quarantine of the donor within the last 12 months?




Stem cell source

Due to the corona crisis, we are currently using ... for patients who we originally wanted to transplant with bone marrow.




COVID19 after alloSCT

Did you have adult patients who became infected with SARS-CoV-2 after cell therapy at your center?



If yes, what was the outcome of these adult patients?



Required ICU treatment:

COVID-19 after autologous SCT	16,7 %
COVID-19 after allogeneic SCT	24,6 %